Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

89 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).
Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, Reiser M, Nickenig C, Clemens M, Peter N, Bokemeyer C, Eimermacher H, Ho A, Hoffmann M, Mertelsmann R, Trümper L, Balleisen L, Liersch R, Metzner B, Hartmann F, Glass B, Poeschel V, Schmitz N, Ruebe C, Feller AC, Loeffler M; German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Pfreundschuh M, et al. Among authors: ziepert m. Lancet Oncol. 2008 Feb;9(2):105-16. doi: 10.1016/S1470-2045(08)70002-0. Epub 2008 Jan 15. Lancet Oncol. 2008. PMID: 18226581 Clinical Trial.
Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: I. A randomized dose escalation and feasibility study with bi- and tri-weekly regimens.
Trümper L, Zwick C, Ziepert M, Hohloch K, Schmits R, Mohren M, Liersch R, Bentz M, Graeven U, Wruck U, Hoffmann M, Metzner B, Hasenclever D, Loeffler M, Pfreundschuh M; German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Trümper L, et al. Among authors: ziepert m. Ann Oncol. 2008 Mar;19(3):538-44. doi: 10.1093/annonc/mdm497. Epub 2008 Jan 22. Ann Oncol. 2008. PMID: 18212092 Free article. Clinical Trial.
MicroRNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomas.
Roehle A, Hoefig KP, Repsilber D, Thorns C, Ziepert M, Wesche KO, Thiere M, Loeffler M, Klapper W, Pfreundschuh M, Matolcsy A, Bernd HW, Reiniger L, Merz H, Feller AC. Roehle A, et al. Among authors: ziepert m. Br J Haematol. 2008 Sep;142(5):732-44. doi: 10.1111/j.1365-2141.2008.07237.x. Epub 2008 Jun 3. Br J Haematol. 2008. PMID: 18537969 Free article.
Equitoxicity of bolus and infusional etoposide: results of a multicenter randomised trial of the German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL) in elderly patients with refractory or relapsing aggressive non-Hodgkin lymphoma using the CEMP regimen (cisplatinum, etoposide, mitoxantrone and prednisone).
Zwick C, Birkmann J, Peter N, Bodenstein H, Fuchs R, Hänel M, Reiser M, Hensel M, Clemens M, Zeynalova S, Ziepert M, Pfreundschuh M; German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL). Zwick C, et al. Among authors: ziepert m. Ann Hematol. 2008 Sep;87(9):717-26. doi: 10.1007/s00277-008-0500-1. Epub 2008 Jun 28. Ann Hematol. 2008. PMID: 18587579 Clinical Trial.
Favorable impact of the interleukin-4 receptor allelic variant I75 on the survival of diffuse large B-cell lymphoma patients demonstrated in a large prospective clinical trial.
Schoof N, von Bonin F, Zeynalova S, Ziepert M, Jung W, Loeffler M, Pfreundschuh M, Trümper L, Kube D. Schoof N, et al. Among authors: ziepert m. Ann Oncol. 2009 Sep;20(9):1548-1554. doi: 10.1093/annonc/mdp110. Epub 2009 Jun 10. Ann Oncol. 2009. PMID: 19515749 Free article. Clinical Trial.
High-dose CHOP plus etoposide (MegaCHOEP) in T-cell lymphoma: a comparative analysis of patients treated within trials of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).
Nickelsen M, Ziepert M, Zeynalova S, Glass B, Metzner B, Leithaeuser M, Mueller-Hermelink HK, Pfreundschuh M, Schmitz N. Nickelsen M, et al. Among authors: ziepert m. Ann Oncol. 2009 Dec;20(12):1977-84. doi: 10.1093/annonc/mdp211. Epub 2009 Jul 1. Ann Oncol. 2009. PMID: 19570965 Free article. Clinical Trial.
Loss of HLA-DR expression and immunoblastic morphology predict adverse outcome in diffuse large B-cell lymphoma - analyses of cases from two prospective randomized clinical trials.
Bernd HW, Ziepert M, Thorns C, Klapper W, Wacker HH, Hummel M, Stein H, Hansmann ML, Ott G, Rosenwald A, Müller-Hermelink HK, Barth TF, Möller P, Cogliatti SB, Pfreundschuh M, Schmitz N, Trümper L, Höller S, Löffler M, Feller AC; German High Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Bernd HW, et al. Among authors: ziepert m. Haematologica. 2009 Nov;94(11):1569-80. doi: 10.3324/haematol.2009.008862. Haematologica. 2009. PMID: 19880780 Free PMC article.
A functional polymorphism in the NAD(P)H oxidase subunit CYBA is related to gene expression, enzyme activity, and outcome in non-Hodgkin lymphoma.
Hoffmann M, Schirmer MA, Tzvetkov MV, Kreuz M, Ziepert M, Wojnowski L, Kube D, Pfreundschuh M, Trümper L, Loeffler M, Brockmöller J; German Study Group for High-Grade Non-Hodgkin Lymphoma. Hoffmann M, et al. Among authors: ziepert m. Cancer Res. 2010 Mar 15;70(6):2328-38. doi: 10.1158/0008-5472.CAN-09-2388. Epub 2010 Mar 9. Cancer Res. 2010. PMID: 20215507
89 results